Reconciled ClinicalTrials.gov v2 Protocol Specification
| Protocol Field | Verified Registry Value |
|---|---|
| NCT Identifier | NCT06140524 |
| Consolidated Lead Sponsor | Regeneron Pharmaceuticals |
| Therapeutic Condition Cohort | Oncology and Hematology |
| Clinical Trial Phase | Phase II |
| Overall Recruitment Status | RECRUITING |
| Registered Enrollment | 116 participants (ESTIMATED) |
| Registered Start Date | 2024-09-16 |
| WhyStopped Classification | Not Stopped |
Named U.S. Hospital Clinical Research Sites
| Hospital Research Site | Location | Site Profile |
|---|---|---|
| Johns Hopkins Hospital and Kimmel Cancer Center | Baltimore, MD | Open Hospital Dossier -> |
| Dana-Farber Cancer Institute | Boston, MA | Open Hospital Dossier -> |
| University of Michigan Rogel Cancer Center | Ann Arbor, MI | Open Hospital Dossier -> |
| NYU Langone Health and Perlmutter Cancer Center | New York, NY | Open Hospital Dossier -> |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for Regeneron Pharmaceuticals across sibling Meru public-data platforms.
Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.